The post GM expects next year’s results to top 2025 earnings appeared on BitcoinEthereumNews.com. The GM logo is seen on the facade of the General Motors headquarters in Detroit on March 16, 2021. Rebecca Cook | Reuters DETROIT — General Motors CFO Paul Jacobson on Tuesday said the company expects earnings next year to top its 2025 results, which have performed far better than Wall Street’s expectations. Investors had been hoping to hear comments about 2026 guidance as the automaker reported third-quarter earnings that included raising 2025 guidance and topping Wall Street’s expectations. “Looking ahead to 2026, we have multiple levers to carry our current momentum forward, including progress on [electric vehicle] losses, warranty costs, tariff offsets, regulatory requirements and fixed costs,” Jacobson said. “As a result, we expect next year to be even better than 2025.” The company’s shares were trading up more than 10% on Tuesday. The stock closed Monday at $58 per share. Jacobson also said the automaker will continue to repurchase shares, which the company has been aggressive about in recent years. At the end of the third quarter, GM’s outstanding shares were at 954 million, a 15% decline from a year earlier. “We’re going to continue to just focus on executing the business and executing the plan, and that’s worked really well for us and we expect it will in ’26,” Jacobson said. Stock Chart IconStock chart icon GM stock in 2025. Jacobson and GM CEO Mary Barra said the company’s top priority is returning adjusted profit margins in North America – its core market – to 8% to 10% but did not give a time frame for meeting that goal. The margin was 6.2% during the third quarter. GM’s updated 2025 guidance includes adjusted earnings before interest and taxes of between $12 billion and $13 billion, or $9.75 to $10.50 adjusted EPS, up from $10 billion to $12.5… The post GM expects next year’s results to top 2025 earnings appeared on BitcoinEthereumNews.com. The GM logo is seen on the facade of the General Motors headquarters in Detroit on March 16, 2021. Rebecca Cook | Reuters DETROIT — General Motors CFO Paul Jacobson on Tuesday said the company expects earnings next year to top its 2025 results, which have performed far better than Wall Street’s expectations. Investors had been hoping to hear comments about 2026 guidance as the automaker reported third-quarter earnings that included raising 2025 guidance and topping Wall Street’s expectations. “Looking ahead to 2026, we have multiple levers to carry our current momentum forward, including progress on [electric vehicle] losses, warranty costs, tariff offsets, regulatory requirements and fixed costs,” Jacobson said. “As a result, we expect next year to be even better than 2025.” The company’s shares were trading up more than 10% on Tuesday. The stock closed Monday at $58 per share. Jacobson also said the automaker will continue to repurchase shares, which the company has been aggressive about in recent years. At the end of the third quarter, GM’s outstanding shares were at 954 million, a 15% decline from a year earlier. “We’re going to continue to just focus on executing the business and executing the plan, and that’s worked really well for us and we expect it will in ’26,” Jacobson said. Stock Chart IconStock chart icon GM stock in 2025. Jacobson and GM CEO Mary Barra said the company’s top priority is returning adjusted profit margins in North America – its core market – to 8% to 10% but did not give a time frame for meeting that goal. The margin was 6.2% during the third quarter. GM’s updated 2025 guidance includes adjusted earnings before interest and taxes of between $12 billion and $13 billion, or $9.75 to $10.50 adjusted EPS, up from $10 billion to $12.5…

GM expects next year’s results to top 2025 earnings

2025/10/21 23:24

The GM logo is seen on the facade of the General Motors headquarters in Detroit on March 16, 2021.

Rebecca Cook | Reuters

DETROIT — General Motors CFO Paul Jacobson on Tuesday said the company expects earnings next year to top its 2025 results, which have performed far better than Wall Street’s expectations.

Investors had been hoping to hear comments about 2026 guidance as the automaker reported third-quarter earnings that included raising 2025 guidance and topping Wall Street’s expectations.

“Looking ahead to 2026, we have multiple levers to carry our current momentum forward, including progress on [electric vehicle] losses, warranty costs, tariff offsets, regulatory requirements and fixed costs,” Jacobson said. “As a result, we expect next year to be even better than 2025.”

The company’s shares were trading up more than 10% on Tuesday. The stock closed Monday at $58 per share.

Jacobson also said the automaker will continue to repurchase shares, which the company has been aggressive about in recent years. At the end of the third quarter, GM’s outstanding shares were at 954 million, a 15% decline from a year earlier.

“We’re going to continue to just focus on executing the business and executing the plan, and that’s worked really well for us and we expect it will in ’26,” Jacobson said.

Stock chart icon

GM stock in 2025.

Jacobson and GM CEO Mary Barra said the company’s top priority is returning adjusted profit margins in North America – its core market – to 8% to 10% but did not give a time frame for meeting that goal. The margin was 6.2% during the third quarter.

GM’s updated 2025 guidance includes adjusted earnings before interest and taxes of between $12 billion and $13 billion, or $9.75 to $10.50 adjusted EPS, up from $10 billion to $12.5 billion, or $8.25 to $10 adjusted EPS, and adjusted automotive free cash flow of $10 billion to $11 billion, up from $7.5 billion to $10 billion.

“This commentary is encouraging and consistent with our incoming view that automakers could convey positive messaging beyond 2025,” TD Cowen analyst Itay Michaeli said Tuesday in an investor note about 2026.

RBC Capital Markets analyst Tom Narayan said he expects 2026 analyst consensus to “move significantly higher” following the third-quarter results and adjusted guidance.

Citi’s Michael Ward said the recent results and guidance signal a larger cultural change for GM: “In the past it was said it was difficult to turn the big ship GM too quickly. Given the changing landscape, GM has found a way to turn it much faster than in the past.”

— CNBC’s Michael Bloom contributed to this report.

Correction: At the end of the third quarter, GM’s outstanding shares were at 954 million. An earlier version mischaracterized the figure.

Source: https://www.cnbc.com/2025/10/21/gm-2025-earnings.html

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Share Insights

You May Also Like

New Viral Presale on XRPL: DeXRP Surpassed $6.4 Million

New Viral Presale on XRPL: DeXRP Surpassed $6.4 Million

The post New Viral Presale on XRPL: DeXRP Surpassed $6.4 Million  appeared on BitcoinEthereumNews.com. One of the most talked-about ecosystems in the cryptocurrency space is the XRP Ledger (XRPL), and DeXRP, the first Presale on XRPL, recently made headlines for its growth story. Attracting over 9,300 investors globally, the project has now raised over $6.4 million and is rapidly emerging as one of the most viral cryptocurrency launches of 2025. By integrating AMM and Order Book trading with a cutting-edge LP system and an open voting process for holders, DeXRP hopes to establish itself as the preferred trading destination for the XRPL community. What is DeXRP?  As the first decentralized exchange (DEX) based on XRPL, DeXRP is taking center stage as XRP continues to solidify its place in the global market. Massive expectation has been generated by the combination of DeXRP’s ambition for an advanced trading platform and XRPL’s established infrastructure, which is renowned for its quick transactions, cheap fees, and institutional-ready capabilities. In contrast to a lot of speculative presales, DeXRP’s development shows both institutional interest and community-driven momentum. Its early achievement of the $6.4 million milestone demonstrates how rapidly investors are realizing its potential. DeXRP Presale Success More than 9,300 distinct wallets have already joined the DeXRP presale, indicating a high level of interest from around the world. A crucial aspect is highlighted by the volume and variety of participation: DeXRP is not merely a niche project; rather, it is emerging as a major force in the XRPL ecosystem. DeXRP’s recent collaborations with WOW Earn and Micro3, as well as its sponsorship of the WOW Summit in Hong Kong, are also contributing factors to this uptick in investor confidence. These actions are blatant attempts to increase the company’s awareness among institutional players and crypto-native groups. The Forbes article summed it up: DeXRP is embedding credibility where others chase hype, marking it as…
Share
2025/09/18 20:14
Share
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
2025/09/18 05:26
Share